Dogwood Therapeutics filings document the regulatory record of a Delaware development-stage biopharmaceutical company focused on pain and neuropathy medicines. Its 8-K reports include financial results, Regulation FD shareholder letters, corporate updates, and material-event disclosures tied to the Halneuron® and SP16 IV development programs.
Proxy and meeting filings cover stockholder voting matters, governance, executive compensation, equity incentive plans, and Nasdaq-related approvals for warrant exercises and common stock issuances. The filing record also documents capital-structure matters, securities purchase agreements, equity awards, and risk-oriented disclosures associated with a clinical-stage biotechnology issuer.
Dogwood Therapeutics, Inc. (DWTX) reported that Sealbond Limited acquired 4,098,360 common shares in a private placement on October 26, 2026, at $1.22 per share, bringing its directly held position to 25,920,693 shares. The shares were acquired under a Subscription Agreement dated October 19, 2026. Conjoint Inc. directly held 2,842,638 shares as of October 26, 2026; it is in a wholly owned chain ending with CK Life Sciences Intl (Holdings) Inc. (CKLS), which disclaimed Section 16 beneficial ownership except to the extent, if any, of its pecuniary interest. Remarks state that Yu Ying Choi Alan Abel, CKLS’s Deputy Chairman, and Toh Kean Meng Melvin, CKLS’s Vice President and Chief Scientific Officer and Executive Director, were appointed to Dogwood’s board and deputized to represent the reporting person. By virtue of their representation, the reporting person may be deemed a director by deputization for Section 16; each individual filed a separate Section 16 report.
Dogwood Therapeutics, Inc. completed a private placement in which Sealbond Limited purchased 4,098,360 common shares from the company on October 26, 2026, at $1.22 per share, for aggregate consideration of approximately $5,000,000 using working capital funds.
After the placement, Sealbond directly held 25,920,693 shares, or approximately 67.8%, and Conjoint Inc. directly held 2,842,638 shares, or approximately 7.4%. CK Life Sciences Int'l., (Holdings) Inc., the indirect parent of both, reported beneficial ownership of 28,763,331 shares, or approximately 75.2%, and may be deemed to have voting and dispositive power over their shares. The percentages use 38,227,913 shares outstanding, including 34,129,553 shares outstanding as of September 30, 2026, and the 4,098,360 shares issued in the placement.
On October 19, 2026, Dogwood Therapeutics, Inc. (DWTX) agreed to issue and sell 4,098,360 common shares to Sealbond Limited in a private placement at $1.22 per share; closing is expected on or before October 29, 2026. Under a registration rights agreement, Dogwood must file a resale registration statement no later than the 15th day following October 19, 2026. It also agreed to use reasonable best efforts to obtain effectiveness as soon as reasonably practicable after filing, and no later than the fifth business day after receiving qualifying SEC notice. Dogwood bears registration fees and expenses other than selling expenses, which Sealbond bears.
As of September 30, 2026, Sealbond reported beneficial ownership of 21,822,333 shares, or 63.9%, and Conjoint Inc. reported 2,842,638 shares. Their indirect parent, CK Life Sciences Int'l., (Holdings) Inc., reported beneficial ownership of 24,664,971 shares, or 72.3%. The ownership percentages are based on 34,129,553 shares outstanding as of that date.
Dogwood Therapeutics, Inc. agreed to issue and sell Sealbond Limited 4,098,360 shares of common stock at $1.22 per share in a private placement expected to close on or prior to October 29, 2026. Gross proceeds are expected to be approximately $5 million before offering expenses. Sealbond beneficially owned approximately 63.9% of Dogwood’s outstanding common stock before the placement and is considered an affiliate.
Dogwood intends to use proceeds for general working capital. The company also said net proceeds are expected to fund Halneuron Phase 3 preparatory activities, working capital and general corporate purposes, and that, upon closing, proceeds are expected to extend operational runway through March 2027. Dogwood agreed to file a resale registration statement no later than the 15th day after the registration rights agreement and to use reasonable best efforts to have it declared effective as soon as reasonably practicable, but no later than the fifth business day after notice that the SEC will not review it or has no further comments. The Halneuron Phase 2b trial’s topline readout was expected in November 2026.
Dogwood Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2026 and remains a pre-revenue, development-stage biopharmaceutical company focused on cancer-related pain and chemotherapy-induced neuropathy.
The company posted a net loss of $11.5 million for the quarter and $16.5 million for the first half of 2026, driven by $3.2 million in research and development, $1.6 million in general and administrative expenses, and a $9.2 million IPR&D impairment in the quarter. A net non-cash IPR&D impairment charge of $6.7 million was recognized after a related deferred tax benefit.
Cash and cash equivalents increased to $9.6 million as of June 30, 2026, helped by $11.4 million of net proceeds from a January 2026 equity offering, but operating activities used $8.2 million of cash in the first half. Accumulated deficit reached $124.6 million and management disclosed substantial doubt about the company’s ability to continue as a going concern beyond the fourth quarter of 2026 without additional financing.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of Dogwood Therapeutics, Inc. common stock. They collectively report 3,384,798 shares, representing 9.99% of the class, with shared power to vote and dispose of all reported shares and no sole voting or dispositive power.
The shares are held directly by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company for which Armistice Capital serves as investment manager under an Investment Management Agreement. Through this role, Armistice Capital and Mr. Boyd may be deemed to beneficially own the shares, while the Master Fund has the economic right to dividends and sale proceeds and disclaims beneficial ownership due to its lack of voting and dispositive power.
Dogwood Therapeutics, Inc. reported second quarter 2026 results with no revenue and a focus on advancing its non-opioid pain pipeline. The Halneuron® Phase 2b trial in chemotherapy-induced neuropathic pain is on track for top-line data in fall 2026, with 217 patients enrolled and plans to enroll over 220 patients to provide more than 80% statistical power.
For the quarter ended June 30, 2026, research and development expenses were $3.25 million and general and administrative expenses were $1.63 million. Dogwood recorded a non-cash IPR&D impairment charge of $9.19 million, leading to a net loss attributable to common stockholders of $11.53 million, or $0.34 per share. Cash was $9.61 million as of June 30, 2026.
Strategically, Dogwood highlighted a worldwide development and commercialization partnership for legacy antiviral assets with potential value of up to $100 million for the company and its CVR holders, the start of a Phase 2b long-term extension study of Halneuron®, and a fully National Cancer Institute–funded forthcoming SP16 IV Phase 1b trial.
Dogwood Therapeutics, Inc. held its annual stockholder meeting, where investors approved an amendment to the Certificate of Incorporation to increase the number of authorized common and preferred shares. Stockholders also elected seven directors, ratified Forvis Mazars, LLP as auditor for 2026, and endorsed executive pay.
Holders of 31,791,500 common shares, representing 95.17% of the voting power as of the record date, were present in person or by proxy, providing a strong quorum. Stockholders supported holding advisory votes on executive compensation every year, and the Board agreed to include this annual vote in future proxy materials.
Dogwood Therapeutics, Inc. director Abel De La Rosa received a grant of stock options, giving the right to buy 16,800 shares of common stock. The options have an exercise price of $1.50 per share and were awarded at no cost as equity compensation.
After this grant, De La Rosa holds stock options for 16,800 underlying shares directly. The options become exercisable starting on June 16, 2027 and expire on June 16, 2036, providing long-term potential ownership if exercised in the future.
Thomas John C reported acquisition or exercise transactions in this Form 4 filing.
Dogwood Therapeutics director Thomas John C received a grant of stock options giving him the right to buy 16,800 shares of common stock at $1.50 per share. These options expire on June 16, 2036 and are held directly, with 16,800 derivative securities reported following the grant. This is a compensation-related award rather than an open-market purchase or sale.